Literature DB >> 1993845

Administration of IL-7 to mice with cyclophosphamide-induced lymphopenia accelerates lymphocyte repopulation.

P J Morrissey1, P Conlon, S Braddy, D E Williams, A E Namen, D Y Mochizuki.   

Abstract

Lymphopenia was induced in mice by a single injection of cyclophosphamide. IL-7 or a control protein were administered to the mice twice daily and the cellularity and composition of the spleen, lymph node, bone marrow, and thymus were determined at various time points thereafter. In comparison to the control cyclophosphamide-treated mice, animals receiving cyclophosphamide and IL-7 had an accelerated regeneration of splenic and lymph node cellularity. There was no significant difference in the rate of recovery of the bone marrow and thymus of the control and IL-7-treated mice. Assessment of the pre-B cell compartment revealed a dramatic increase in total pre-B cell numbers in the spleen and bone marrow of the IL-7-treated mice as measured by both flow microfluorimetry and a pre-B cell colony-forming assay. This was followed in a few days by a significant increase in surface IgM+B cell numbers to levels above normal values in both the spleen and lymph node. IL-7 administration to cyclophosphamide-treated mice also resulted in an accelerated recovery of peripheral CD4+ and CD8+ cell numbers in the spleen and lymph node. The numbers of CD8+ cells were increased by twofold over normal levels in cyclophosphamide-treated mice receiving IL-7. Myeloid recovery was determined in cyclophosphamide treated mice by assessing the numbers of CFU-granulocyte-macrophage and Mac 1+ cells. There was no significant difference in myeloid recovery between cyclophosphamide-treated mice receiving IL-7 or control protein. These results suggest that administration of IL-7 after chemical-induced lymphopenia may have therapeutic benefits in shortening the period required to achieve normal lymphoid cellularity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1993845

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Variations in serum IL-7 and 90K/Mac-2 binding protein (Mac-2 BP) levels analysed in cohorts of HIV-1 patients and correlated with clinical changes following antiretroviral therapy.

Authors:  E C Darcissac; V Vidal; X De La Tribonniere; Y Mouton; G M Bahr
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

2.  Development of a diverse human T-cell repertoire despite stringent restriction of hematopoietic clonality in the thymus.

Authors:  Martijn H Brugman; Anna-Sophia Wiekmeijer; Marja van Eggermond; Ingrid Wolvers-Tettero; Anton W Langerak; Edwin F E de Haas; Leonid V Bystrykh; Jon J van Rood; Gerald de Haan; Willem E Fibbe; Frank J T Staal
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-19       Impact factor: 11.205

3.  IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells.

Authors:  Steven A Rosenberg; Claude Sportès; Mojgan Ahmadzadeh; Terry J Fry; Lien T Ngo; Susan L Schwarz; Maryalice Stetler-Stevenson; Kathleen E Morton; Sharon A Mavroukakis; Michel Morre; Renaud Buffet; Crystal L Mackall; Ronald E Gress
Journal:  J Immunother       Date:  2006 May-Jun       Impact factor: 4.456

Review 4.  Harnessing the biology of IL-7 for therapeutic application.

Authors:  Crystal L Mackall; Terry J Fry; Ronald E Gress
Journal:  Nat Rev Immunol       Date:  2011-05       Impact factor: 53.106

Review 5.  Modulating T-cell homeostasis with IL-7: preclinical and clinical studies.

Authors:  C M Capitini; A A Chisti; C L Mackall
Journal:  J Intern Med       Date:  2009-08       Impact factor: 8.989

6.  Differential effects of interleukin-7 and interleukin-15 on NK cell anti-human immunodeficiency virus activity.

Authors:  Julian J Lum; David J Schnepple; Zilin Nie; Jaime Sanchez-Dardon; Georgina L Mbisa; Jennifer Mihowich; Nanci Hawley; Shanil Narayan; John E Kim; David H Lynch; Andrew D Badley
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

7.  Differential disposition of soluble and liposome-formulated human recombinant interleukin-7: effects on blood lymphocyte population in guinea pigs.

Authors:  T Bui; C Faltynek; R J Ho
Journal:  Pharm Res       Date:  1994-05       Impact factor: 4.200

8.  Increased interleukin-7 plasma levels are associated with recovery of CD4+ T cells in HIV-infected children.

Authors:  Rafael Correa; Salvador Resino; M Angeles Muñoz-Fernández
Journal:  J Clin Immunol       Date:  2003-09       Impact factor: 8.317

9.  Expression and function of the interleukin 7 receptor in murine lymphocytes.

Authors:  T Sudo; S Nishikawa; N Ohno; N Akiyama; M Tamakoshi; H Yoshida; S Nishikawa
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

10.  Impact of Hepatitis C Virus on the Circulating Levels of IL-7 in HIV-1 Coinfected Women.

Authors:  Jerome Kerzerho; Elizabeth J McIlvaine; Patricia Anthony; Wendy J Mack; Chia-Hao Wang; Toni Frederick; Eva Operskalski; Zhi Chen; Lena Al-Harthi; Alan Landay; Mary A Young; Phyllis C Tien; Michael Augenbraun; Howard D Strickler; Omid Akbari; Elizabeth T Golub; Gerald B Sharp; Andrea Kovacs
Journal:  J Acquir Immune Defic Syndr       Date:  2016-02-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.